• Publications
  • Influence
Tacrolimus: a further update of its use in the management of organ transplantation.
TLDR
The reduced incidence of rejection episodes in renal transplant recipients receiving tacrolimus translated into a better cost effectiveness relative to cyclosporin microemulsion treatment, which was reflected in improved cost effectiveness.
Meropenem: a review of its use in the treatment of serious bacterial infections.
TLDR
Its low propensity for inducing seizures means that it is suitable for treating bacterial meningitis and is the only carbapenem approved in this indication.
Atazanavir: a review of its use in the management of HIV-1 infection.
TLDR
Atazanavir, whether unboosted or boosted, was generally well tolerated and appeared to be associated with less marked metabolic effects, including less alteration of lipid levels, than other PIs, and continues to have a role as a component of ART regimens in patients with HIV-1 infection.
Trabectedin : a review of its use in the management of soft tissue sarcoma and ovarian cancer.
TLDR
Intravenous trabectedin administered once every 3 weeks is approved as monotherapy in Europe for use in patients with advanced soft tissue sarcoma (STS) after failure of standard therapy with anthracyclines or ifosfamide, or who are unsuited to receive these agents.
Ranolazine: a review of its use in chronic stable angina pectoris.
TLDR
In patients with chronic stable angina, ranolazine ER monotherapy was shown to improve exercise duration at trough plasma drug concentration in a dose-dependent manner compared with placebo, and the drug was effective as adjunctive therapy in patients whose condition was not controlled adequately with conventional antianginal therapy.
Trastuzumab: a review of its use in the management of HER2-positive metastatic and early-stage breast cancer.
TLDR
The addition of intravenous trastuzumab to first-line chemotherapy improved the time to disease progression, objective response rate, duration of response, and overall survival in randomised, multicentre trials in women with HER2-positive metastatic breast cancer.
Pranlukast: a review of its use in the management of asthma.
TLDR
In clinical trials, pranlukast was well tolerated in adult and paediatric patients with asthma, with an adverse event profile similar to that of placebo, and is a useful therapeutic option (with as-required short-acting beta(2)-agonists), either as preventative monotherapy for the treatment of mild persistent asthma or in conjunction with inhaled corticosteroid dosages.
Vildagliptin: a review of its use in the management of type 2 diabetes mellitus.
TLDR
Oral vildagliptin in combination with metformin, a sulfonylurea or a thiazolidinedione improved glycaemic control in adults with type 2 diabetes and appeared to slow the progression of beta-cell degeneration in trials of 24-52 weeks' duration.
Bevacizumab: a review of its use in metastatic colorectal cancer.
TLDR
The addition of bevacizumab to fluoropyrimidine-based chemotherapy, with or without irinotecan or oxaliplatin, in both the first- and second-line treatment of metastatic colorectal cancer, significantly increased median progression-free survival or time to disease progression in most randomized controlled trials.
Escitalopram: a review of its use in the management of major depressive disorder.
TLDR
Clinical and pharmacoeconomic data indicate that escitalopram is an effective first-line option in the management of patients with MDD.
...
1
2
3
4
5
...